<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316808</url>
  </required_header>
  <id_info>
    <org_study_id>PCL_2011_Kal</org_study_id>
    <nct_id>NCT02316808</nct_id>
  </id_info>
  <brief_title>Cholesterol-lowering Effects of Plant Stanol Ester</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raisio Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Raisio Group</source>
  <brief_summary>
    <textblock>
      Efficacy of plant stanols as esters on LDL-cholesterol reduction is well documented.
      LDL-cholesterol lowering efficacy of the ingredient administered in a smoothie is less well
      known.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change (proportional) in LDL-C from baseline up to 4-weeks after plant stanol ester smoothie drink consumption.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Placebo smoothie</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Plant stanol ester smoothie</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Plant stanol ester</intervention_name>
    <description>Smoothie that contains plant stanol ester</description>
    <arm_group_label>Plant stanol ester smoothie</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Smoothie that contains placebo</description>
    <arm_group_label>Placebo smoothie</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  total cholesterol concentration ≥ 200 mg/dL and &lt; 300 mg/dL, and or LDL-C
             concentration ≥ 130 mg/dL and &lt; 180 mg/dL

          -  were willing to consume control or plant stanol ester smoothie drinks two bottles per
             day immediately after a meal for four weeks,

          -  reachable by phone

          -  willing to declare written informed consent

          -  agreed in accordance with data protective stipulations and readiness to participate in
             the trial and to adhere to the study conditions.

        Exclusion Criteria:

          -  Pregnant women

          -  obese

          -  diabetic subjects or subjects with random plasma glucose concentration &gt; 200 mg/dL

          -  hyperthyroidism, a history of metabolic, endocrine and kidney disorders

          -  acute or chronic severe diseases possibly interfering with the evaluation of the
             outcome of the clinical trial (such as AIDS, tumor diseases, malignant hypertension,
             cardiac insufficiency according to NYHA III-IV)

          -  taking lipid-lowering medication or other medications likely to affect lipid
             metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <last_update_submitted>December 19, 2014</last_update_submitted>
  <last_update_submitted_qc>December 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

